Antitumor and antimitotic activity of aminochalcones in human cancer cells with differential P-glycoprotein expression
DOI:
https://doi.org/10.48797/sl.2026.488Keywords:
PosterAbstract
Background: Cancer remains a leading cause of mortality, with drug resistance, particularly mediated by P-glycoprotein (P-gp), limiting therapeutic efficacy [1]. Chalcones have emerged as promising anticancer agents due to their ability to inhibit tubulin polymerization and disrupt microtubule dynamics [2]. In this context, dual‑targeting strategies combining antimitotic activity with P‑gp inhibition, including chalcone‑based derivatives, have recently been reported as a means to overcome multidrug resistance [3]. Objective: This study aimed to evaluate the antitumor and antimitotic activity of eight aminochalcone derivatives in human cancer cell lines of diverse origins: melanoma (A375-C5), breast adenocarcinoma (MCF-7), non-small cell lung carcinoma (NCI-H460), ovarian carcinoma with dual resistance to paclitaxel and carboplatin (OVCAR8 PTX/CBP-R), and colon adenocarcinoma (HCT-15), each exhibiting different levels of P-glycoprotein expression, with HCT-15 as a well-established model for multidrug resistance studies. Methods: The antitumor activity of all compounds was assessed in five cancer cell lines using the sulforhodamine B assay to determine the GI50 values at 48 h (defined as the concentration required to inhibit 50% of cell growth), with doxorubicin as a control. Selectivity indices were calculated using the non-cancerous breast MCF10A cell line. Antimitotic activity was evaluated by phase-contrast microscopy and DAPI staining. Results: Seven of the eight compounds demonstrated potent cytotoxic activity across all tested cancer cell lines. The strongest selectivity was observed in HCT-15 cells, which highly express P-gp. All compounds exhibited antimitotic activity, although the extent varied among derivatives. Conclusions: These findings support the potential of aminochalcone derivatives as antimitotic and anticancer agents, particularly for targeting P-gp-mediated drug-resistant cancer cells.
References
1. Dong, J. et al. Strategies to overcome cancer multidrug resistance (MDR) through targeting P‑glycoprotein (ABCB1): An updated review. Pharmacol Ther 2023, 249, 108488, doi:10.1016/j.pharmthera.2023.108488.
2. Hashem, H. et al. Synthesis of new thiazole‑privileged chalcones as tubulin polymerization inhibitors with potential anticancer activities. Pharmaceutics 2024, 17, 1154, doi:10.3390/ph17091154.
3. Liu, Z. et al. Design and synthesis of novel imidazole‑chalcone derivatives as microtubule protein polymerization inhibitors to treat cervical cancer and reverse cisplatin resistance. Bioorg Chem 2024, 147, 107310, doi:10.1016/j.bioorg.2024.107310.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Chloé Golfier, Patrícia Ferreira, Henrique Assunção, Daniela Pereira, Honorina Cidade, Patrícia M. A. Silva, Hassan Bousbaa
This work is licensed under a Creative Commons Attribution 4.0 International License.
In Scientific Letters, articles are published under a CC-BY license (Creative Commons Attribution 4.0 International License), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use).
The author is the owner of the copyright.
